Xencor to Present at the H.C. Wainwright Bioconnect Virtual Conference Read more about Xencor to Present at the H.C. Wainwright Bioconnect Virtual Conference
Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting Read more about Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting
Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor Read more about Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor
Xencor to Present at Upcoming Investor Conferences Read more about Xencor to Present at Upcoming Investor Conferences
Xencor Presents Updated Data from the Phase 1 Study of Vudalimab, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual Meeting Read more about Xencor Presents Updated Data from the Phase 1 Study of Vudalimab, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual Meeting
Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody Programs and IL-12 Cytokine, XmAb662, at the SITC Annual Meeting Read more about Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody Programs and IL-12 Cytokine, XmAb662, at the SITC Annual Meeting
Xencor Reports Third Quarter 2021 Financial Results and Announces Encouraging Preliminary Data from Ongoing Phase 1 Study of Potency-reduced IL15-Fc Cytokine, XmAb306 Read more about Xencor Reports Third Quarter 2021 Financial Results and Announces Encouraging Preliminary Data from Ongoing Phase 1 Study of Potency-reduced IL15-Fc Cytokine, XmAb306
Xencor to Present Data from the Phase 1 Study of Plamotamab in B-Cell Malignancies at the American Society of Hematology Annual Meeting Read more about Xencor to Present Data from the Phase 1 Study of Plamotamab in B-Cell Malignancies at the American Society of Hematology Annual Meeting
Xencor Presents Clinical Data from the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS’ Multidisciplinary NET Medical Virtual Symposium Read more about Xencor Presents Clinical Data from the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS’ Multidisciplinary NET Medical Virtual Symposium
Xencor to Present at Upcoming Investor Conferences Read more about Xencor to Present at Upcoming Investor Conferences
